Liquid biopsy for early detection of pancreatic ductal adenocarcinoma

Key Points:

• Pancreatic cancer incidence and mortality are projected to rise significantly by 2030, with an increasing burden highlighted in U.S. cancer statistics reports from 2014 to 2025.
• Advances in early detection methods, including deep learning algorithms analyzing disease trajectories and liquid biopsy techniques using 5-hydroxymethylcytosine and microRNA signatures, show promise for identifying pancreatic cancer at resectable stages.
• Surveillance studies in high-risk individuals, including those with familial predisposition or pancreatic cystic lesions, demonstrate improved early-stage detection and survival outcomes, supporting the value of targeted screening protocols.
• Clinical guidelines and expert consortium recommendations emphasize the importance of organized, risk-based pancreatic cancer screening, incorporating genetic testing and endoscopic surveillance for high-risk populations.
• Emerging biomarkers, multi-analyte blood tests, and machine learning models are being validated to enhance diagnostic accuracy and prognostication, with ongoing research focused on integrating these tools into clinical practice for better early detection and treatment selection.